Previous 10 | Next 10 |
Record quarterly revenue driven by strength in COVID-19 testing and growth in lung diagnostic testing Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020...
Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraterni...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Ryan Siurek has joined the company as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Financial Officer. “I am very ple...
Biodesix (BDSX) launches and initiates recruitment of a first-in-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society policy statement on the early detection of lung cancer.The Nodify XL2 classifier clinical utility study in low to moder...
Dr. Gerard A. Silvestri of Medical University of South Carolina Named Principal Investigator Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a first-in-class biomarker study alig...
Insider activity is getting increasingly informative to follow up during this tough market environment. Insider activity declined significantly in November, indicating that they believe the market is overvalued. However, one can still find very interesting stocks by following sign...
Biodesix (BDSX): Q3 EPS of -$31.93 may not be comparable to consensus of -$0.26.Revenue of $9.19M (+133.2% Y/Y) beats by $0.7M.Press Release For further details see: Biodesix EPS of -$31.93
Generates record quarterly revenue of $9.2 million Raises net proceeds of $63 million through initial public offering Adds to the significant and growing body of evidence demonstrating the clinical value of its portfolio of blood based diagnostic tests for lung disease...
Assessment Confirms Test Performance After Two Years of Surveillance Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2 ® lu...
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 million at a $4.4 billion market cap. Street research is expected for 11 companies...
News, Short Squeeze, Breakout and More Instantly...
Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive, data-driven measurement pro...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference Presentation and 1x1...
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society ...